Pharma consultancy Accession receives private investment

22 March 2021 3 min. read
More news on

Pharmaceutical advisory firm Accession Healthcare Consulting has received private investment to maintain its current growth rate and support its future growth plans. Mid-market investment firm Alantra advised Accession on the deal.

Founded by Elliot Rosen and Lindsey Rosen in 2011, Accession Healthcare Consulting delivers global value and access services to the world’s largest biopharma companies. Using digital technology to enable market access for clients, Accession’s proprietary digital products help pharmaceutical businesses develop and launch new pharma products on the market, transforming how they engage with their customers in the process.

As the firm looks to grow its offering in its tenth year in business, Accession has received private investment from a group of healthcare and technology investors. The investment will support the firm’s strong performance, and accelerate its ambitious growth plans. This includes the provision of the means to build out associated strategic resources and capabilities, as well as for a large-scale increase in headcount across the organisation.

Pharma consultancy Accession receives private investment

Lindsey Rosen, Co-founder and Director of Accession, remarked, “We founded Accession with a passion to harness the power of market access to ensure patients gain access to life changing medicines. It’s a passion that has been the beating heart of everything we do. This investment means we can now work on more pharmaceutical breakthroughs, add more value to our clients and ultimately play our part in delivering the best possible outcomes for patients.’’

Accession was recently named as “One to Watch” in the 2020 Alantra Pharma Fast 50 – a yearly ranking of the UK’s fastest-growing privately-owned pharma companies. With regards to this deal, it was mid-market M&A professional services firm Alantra who provided professionals to help Accession through the investment process. The firm was advised by Alantra’s Pharma Services team members Tom Cowap and Anthony Harrington.

According to Cowap, writing in Alantra’s Pharma Fast 50, breakthrough businesses such as Accession “are focused on value creation – for patients, CROs and big pharma alike,” something which sees them “innovating at speed, paving the way for rapid growth.” As a result of this approach, having begun by helping its clients seeking to bring new therapies to the UK market, where the complexities of the NHS bring particular challenges, Accession is now increasingly working in key European and international markets – making the firm an attractive prospect for investment such as this.

Commenting on the deal, Elliot Rosen, Co-founder and Managing Director of Accession, concluded, “This investment marks a major milestone for Accession. I am delighted to be partnering with ambitious and supportive investors to expedite the exciting growth plans we have for the business. I am also delighted for the Accession team, the foundation of our success has always been our commitment to having the brightest talent, and I look forward to seeing their careers fly during this new era for Accession.”